CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of multiple myeloma (MM).
  
  OVERVIEW OF ACTIVITY
  MM is a plasma cell neoplasm that accounts for approximately 19% of all hematologic cancer and carries one of the worst ratios of death to new cases. Although MM represents only 1.8% of all cancer cases diagnosed annually in the United States, practicing clinicians would be hard pressed to identify another area of oncology in which the research database and related treatment implications have evolved more rapidly over the past decade. Research findings with several recently approved therapies and their introduction into the treatment of MM necessitate rapid and consistent access to learning opportunities for clinicians who care for these patients.
  
  To address that need this CME activity, which is conducted in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development, features investigator perspectives on existing and emerging research surrounding the care of patients with MM. By providing access to the latest therapeutic developments and expert perspectives on the disease, this program will assist medical oncologists, hematologists and other community-based clinicians in the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Design and implement a plan of care for patients with newly diagnosed or relapsed/refractory (R/R) multiple myeloma (MM), considering the applicability of existing and emerging clinical trial data.
  • Discuss research data informing the use of monoclonal antibody therapy directed at CD38 for patients with MM, and discern how this strategy can be effectively integrated into clinical management.
  • Appraise recent data with the FDA-approved agent belantamab mafodotin for R/R MM, and identify patients for whom this treatment may be appropriate.
  • Explore available data documenting the activity of chimeric antigen receptor T-cell therapy and bispecific T-cell engagers, and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches on or outside of clinical trial protocols.
  • Recognize treatment-related adverse events associated with newly approved agents in patients with R/R MM, and offer supportive strategies to minimize and manage these toxicities.

  CONTACT INFORMATION
  If you have questions regarding credit, please contact cpdsupport@usf.edu.
  
  

  ACCREDITATION STATEMENT
  USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  POTENTIAL CONFLICTS OF INTEREST
  USF Health and Research To Practice adhere to The Standards for Integrity and Independence in Accredited Continuing Education in all of its continuing professional development activities. It is USF Health’s and Research To Practice’s policy that all persons in a position to influence content in this activity disclose any financial relationship with an ineligible organization. USF Health and Research To Practice have mitigated all conflicts of interest.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Presenting Faculty Members
  
  Sergio A Giralt, MD
  Deputy Division Head of Hematologic Malignancies
  Melvin Berlin Family Chair in Myeloma Research
  Memorial Sloan Kettering Cancer Center
  Professor of Medicine, Weill Cornell Medical College
  New York, New York
  
  Scientific Advisory Board: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Omeros, Pfizer Inc, Sanofi Genzyme; Research Support: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Pfizer Inc, Sanofi Genzyme.
  
  Jonathan L Kaufman, MD
  Associate Professor of Hematology and Medical Oncology
  Winship Cancer Institute of Emory University
  Atlanta, Georgia
  
  Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc.
  
  Peter Voorhees, MD
  Professor of Medicine
  Member, Plasma Cell Disorders Division
  Levine Cancer Institute, Atrium Health
  Charlotte, North Carolina
  
  Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company; Consulting Agreements: GlaxoSmithKline, Novartis, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.
  
  Contributing General Medical Oncologists
  
  Lyle Feinstein, MD
  Attending Physician, Malignant Hematology and Bone Marrow Transplant
  Miami Cancer Institute
  Miami, Florida
  
  No financial interests or affiliations to disclose.
  
  Ranju Gupta, MD
  Attending Physician
  Co-Director, Cardio-Oncology Program
  LVPG Hematology Oncology Associates
  Lehigh Valley Health Network
  Bethlehem, Pennsylvania
  
  Speakers Bureau: Lilly.
  
  Neil Morganstein, MD
  Hematology Oncology
  Atlantic Health System
  Summit, New Jersey
  
  No financial interests or affiliations to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company and Verastem Inc.
  
  USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. USF Health and Research To Practice do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Adaptive Biotechnologies Corporation, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.
  
  Release date: April 2021
  Expiration date: April 2022